Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.07 AUD | +0.86% | -4.07% | +14.96% |
May. 10 | Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents | MT |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Sales 2024 * | 384M 254M | Sales 2025 * | 429M 284M | Capitalization | 574M 379M |
---|---|---|---|---|---|
Net income 2024 * | -83M -54.85M | Net income 2025 * | -2M -1.32M | EV / Sales 2024 * | 1.31 x |
Net cash position 2024 * | 72.1M 47.64M | Net cash position 2025 * | 60.91M 40.25M | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
-6.91
x | P/E ratio 2025 * |
-206
x | Employees | 967 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
Latest transcript on Mayne Pharma Group Limited
1 day | +0.86% | ||
1 week | -4.07% | ||
Current month | +1.43% | ||
1 month | +0.14% | ||
3 months | +30.93% | ||
6 months | +71.60% | ||
Current year | +14.96% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 7.07 | +0.86% | 72 172 |
24-05-10 | 7.01 | -1.54% | 85,754 |
24-05-09 | 7.12 | -0.28% | 159,902 |
24-05-08 | 7.14 | -1.79% | 117,353 |
24-05-07 | 7.27 | 0.00% | 87,693 |
Delayed Quote Australian S.E., May 13, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.96% | 376M | |
+21.09% | 43.27B | |
+25.28% | 22.92B | |
+19.22% | 15.43B | |
+13.51% | 12.95B | |
+44.01% | 11.83B | |
-7.79% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.02% | 5.55B |
- Stock Market
- Equities
- MYX Stock